FHLC offers broader sector exposure at a 0.08% expense ratio, compared with IBB's concentrated biotech focus at 0.44%, but IBB delivered stronger 1-year returns despite higher volatility.
CryptoAlerta — análise de criptomoedas e mercado em tempo real